Harvard Researchers Developed CRISPR Therapy for Dysautonomia

A new base-editing approach restored ELP1 protein expression in laboratory models of this rare genetic condition.

Updated on Oct. 2, 2026 in Biotech

A close-up view of a clear laboratory flask on a white clinical surface, highlighting the precision of medical research. — Harvard University researchers have developed a CRISPR-based gene therapy that addresses the underlying mutation causing familial dysautonomia by restoring protein expression. AI Illustration. Upload story photo >

Live Poll

Should scientific research into rare genetic conditions receive more public and private funding?

Harvard University researchers have developed a CRISPR-based gene therapy that addresses the underlying mutation causing familial dysautonomia. This research-stage treatment has demonstrated the ability to correct the genetic defect in human cells and mouse models.

Why it matters

The development aims to restore function in the ELP1 gene, potentially halting the progressive neurological and visual decline experienced by those with this rare condition. This approach marks a significant step toward addressing the disease at its genetic source.

In vitro testing achieved a 70% on-target mutation correction rate, while off-target editing remained below 0.2%. The therapy utilized AAV2 and AAV9 serotypes—modified, harmless viral delivery vehicles—to carry an intein-split base editing system into cells.

The players

Harvard University

A private research university with an extensive portfolio in genetic engineering, CRISPR development, and translational medicine.

The details

The therapy functions by targeting a specific single-base substitution in the ELP1 gene to restore proper Exon 20 splicing, a process essential for building full-length proteins. Researchers used a split-CRISPR system, which divides the editing machinery into smaller parts to accommodate the limited capacity of adeno-associated virus (AAV) vectors. This mechanism allows the therapeutic components to reassemble only after entering the target cells, increasing the precision of the genetic correction.

Late 1700s: The common ancestor carrying the ELP1 mutation lived.
20 years of age: Visual decline typically begins in patients.
October 2, 2026: Research details were presented at the RNA Leaders conference.

The Tech Race

This research contributes to the broader field of precision genetic medicine by demonstrating that base editing can be adapted for highly specific, rare gene mutations. It positions Harvard at the forefront of efforts to rescue ELP1 gene function through targeted splicing correction.

This development remains in the research stage and is not currently available for patient treatment. Future clinical translation will depend on successful outcomes in phenotypic mouse models and rigorous safety testing to ensure long-term efficacy.

The takeaway

The study confirms that a single-base correction can restore significant levels of functional protein in a disease affecting 350 known patients worldwide. Researchers and families should watch for upcoming results from the planned phenotypic mouse model trials, which will serve as a key milestone for human clinical viability.

What happens next

The research team plans to test the base-editing approach in phenotypic mouse models to assess whether the protein restoration results in a measurable reduction of disease symptoms.